This discussion emphasizes practical implementation. Freedland outlines how urologists and medical oncologists can collaborate to ensure timely therapy initiation and shares insights into patient- and ...
The discussion opens with an overview of the evolving management of high-risk non–muscle invasive bladder cancer (NMIBC) and introduces the session’s goals of reviewing the treatment landscape, recent ...
The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...
Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
Treatment intensification with ARPIs and chemotherapy has transformed mCSPC management, expanding the urologist's role in early treatment phases. Darolutamide is highlighted for its favorable safety ...
Fast track designation accelerates development of [68Ga]Ga-DPI-4452 for ccRCC detection, enhancing FDA engagement and review processes. ITM-94, a gallium-68-radiolabeled PET agent, forms a theranostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback